Inclusion Criteria:

Signed Informed Consent Form; Age ≥ 18 years; History of histologically confirmed
Hodgkin's lymphoma Subjects are eligible for this trial if (1) they have failed at least 1
cycle of chemotherapy, with or without radiotherapy, and if (2) they are considered
incurable by the referring physician, and would be treated with second-line or
subsequent-line salvage regimens, mainly with palliative intent; Clinical laboratory
values ANC > 1500/µL; Platelet count > 75000/µL Hemoglobin > 9 g/dL (may not be transfused
or treated with erythropoietin to maintain or exceed this level) Total bilirubin < 1.6
mg/dL; AST or ALT < 2.5 times the upper limit of normal Serum creatinine < 2.0 mg/dL or
creatinine clearance > 50 mL/min Serum Potassium and Magnesium within normal limits;
Measurable disease (according to the International Working Group response criteria for
HL); ECOG performance status of 0 or 1; Use of an effective means of contraception for
women of childbearing potential and men with partners of childbearing potential (use per
institutional standard); Life expectancy of > 3 months;; At least 4 weeks since last
treatment for HL Willingness and capability to comply with the requirements of the study;

Exclusion Criteria:

Active bacterial or mycotic infection requiring antimicrobial treatment on Day 1;
Pregnancy or lactation; A marked baseline prolongation of QT/QTc interval (e.g. repeated
demonstration of a QTc interval > 450 ms, according to Bazett's correction formula); The
use of concomitant medications that prolong the QT/QTc interval;

Clinically significant cardiovascular disease e.g.:

Uncontrolled hypertension, myocardial infarction, unstable angina New York Heart
Association (NYHA) Grade II or greater congestive heart failure History of any cardiac
arrhythmia requiring medication (irrespective of its severity) Grade II or greater
peripheral vascular disease A history of additional risk factors for TdP (e.g., heart
failure, hypokalemia, family history of Long QT Syndrome); Positive blood test for HIV,
HBV and HCV; Identification of viral DNA by quantitative PCR for EBV (Ebstein Barr virus),
JC virus, CMV (Cytomegalovirus) and Herpes Zoster; History of other disease, metabolic
dysfunction, physical examination finding, or clinical laboratory finding giving
reasonable suspicion of a disease or condition that contraindicates use of an
investigational drug or that might affect interpretation of the results of the study or
render the subject at high risk from treatment complications;